Detalhe da pesquisa
1.
Spatially distinct roles of class Ia PI3K isoforms in the development and maintenance of PTEN hamartoma tumor syndrome.
Genes Dev
; 27(14): 1568-80, 2013 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23873941
2.
Increasing metabolic stability via the deuterium kinetic isotope effect: An example from a proline-amide-urea aminothiazole series of phosphatidylinositol-3 kinase alpha inhibitors.
Bioorg Med Chem Lett
; 26(19): 4729-4734, 2016 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27575470
3.
INPP5A phosphatase is a synthetic lethal target in GNAQ and GNA11-mutant melanomas.
Nat Cancer
; 5(3): 481-499, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38233483
4.
CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non-Small Cell Lung Cancer.
Cancer Res
; 83(24): 4130-4141, 2023 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37934115
5.
Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells.
Proc Natl Acad Sci U S A
; 106(52): 22299-304, 2009 Dec 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-20007781
6.
The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations.
Proc Natl Acad Sci U S A
; 106(1): 268-73, 2009 Jan 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-19116269
7.
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition.
Proc Natl Acad Sci U S A
; 106(46): 19503-8, 2009 Nov 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-19850869
8.
Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C.
Cancer Discov
; 12(6): 1500-1517, 2022 06 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35404998
9.
Reduced pathological angiogenesis and tumor growth in mice lacking GPR4, a proton sensing receptor.
Angiogenesis
; 14(4): 533-44, 2011 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-22045552
10.
PTEN-deficient cancers depend on PIK3CB.
Proc Natl Acad Sci U S A
; 105(35): 13057-62, 2008 Sep 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-18755892
11.
Targeting melanoma with dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors.
Mol Cancer Res
; 7(4): 601-13, 2009 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-19372588
12.
mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
Clin Cancer Res
; 15(5): 1612-22, 2009 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19223496
13.
Heat shock protein 70-mediated sensitization of cells to apoptosis by Carboxyl-Terminal Modulator Protein.
BMC Cell Biol
; 10: 53, 2009 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-19604401
14.
PI3K inhibitors for cancer treatment: where do we stand?
Biochem Soc Trans
; 37(Pt 1): 265-72, 2009 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-19143644
15.
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.
Mol Cancer Ther
; 7(7): 1851-63, 2008 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-18606717
16.
Imidazo[4,5-c]quinolines as inhibitors of the PI3K/PKB-pathway.
Bioorg Med Chem Lett
; 18(3): 1027-30, 2008 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18248814
17.
Dual Inhibition of the Lactate Transporters MCT1 and MCT4 Is Synthetic Lethal with Metformin due to NAD+ Depletion in Cancer Cells.
Cell Rep
; 25(11): 3047-3058.e4, 2018 12 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30540938
18.
Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.
Cancer Res
; 76(2): 390-402, 2016 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26577700
19.
Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α.
J Clin Invest
; 124(4): 1794-809, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24569456
20.
A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition.
Cancer Res
; 74(1): 15-23, 2014 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24322983